Recombinant angiotensin II therapy in a child with cardiac dysfunction and Pandoraea and Candida sepsis
Presented By:
Michael Kim, DO; Jennifer Kasten, MD; Joel Mortensen, PhD; Stuart Goldstein, MD; Meghan Chlebowski, MD
Cincinnati Children's Hospital Medical Center
michael.kim@cchmc.orgOverview:
Recombinant angiotensin II (AT-II) is an emerging drug therapy for refractory hypotension in the critical care setting. Potential responders have disruption of the Renin-Angiotensin-Aldosterone System (RAAS) which can be quantified by serum direct renin levels. We present a case of a child that responded to AT-II in the setting of septic shock and right ventricular dysfunction.
